nach oben

Current Rheumatology Reports

Erschienen in:

01.08.2015 | Orphan Diseases (B Manger, Section Editor)

RS3PE: Clinical and Research Development

verfasst von: Hongbin Li, Roy D. Altman, Qingping Yao

Erschienen in: Current Rheumatology Reports | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Remitting seronegative symmetrical synovitis with pitting edema or RS3PE is a rare elderly-onset rheumatic syndrome. Although there are overlapping clinical manifestations between RS3PE, elderly-onset rheumatoid arthritis, and polymyalgia rheumatica, RS3PE has distinct characteristics. RS3PE can be associated with neoplasia and various rheumatic conditions, suggesting that it may be heterogeneous, and is considered as a paraneoplastic rheumatic disease. The pathogenesis of RS3PE may involve vascular endothelial growth factor and infection in RS3PE based upon limited data. Patients with RS3PE without concomitant malignancy respond well to small doses of glucocorticoids and carry good prognosis.

McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA. 1985;254:2763–7.PubMedCrossRef

Bhakta BB, Pease CT. Late-onset rheumatoid arthritis: is pitting oedema of the hands at onset a good prognostic indicator? Br J Rheumatol. 1997;36:214–9.PubMedCrossRef

Mavragani CP, Moutsopoulos HM. Rheumatoid arthritis in the elderly. Exp Gerontol. 1999;34:463–71.PubMedCrossRef

Schaeverbeke T, Vernhes JP, Bannwarth B, Dehais J. Is remitting seronegative symmetrical synovitis with pitting oedema (RS3PE syndrome) associated with HLA-A2? Br J Rheumatol. 1995;34:889–90.PubMedCrossRef

Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J Rheumatol. 2005;32:1760–1.PubMed

Toussirot E, Berthier S, Wendling D, Tiberghien P. Lack of association between HLA DRB1* alleles and RS3PE syndrome. Ann Rheum Dis. 1998;57:442.PubMedCentralPubMedCrossRef

Serrano Ostoa B, Alvarez Hernández E. Remmiting symmetric seronegative synovitis with pitting edema (RS3PE). Reumatol Clin. 2012;8(3):156--7. doi:10.1016/j.reuma.2011.05.008.

Varshney AN, Kumar N, Tiwari A, et al. Unilateral RS3PE in a patient of seronegative rheumatoid arthritis. Case Rep Rheumatol. 2013;2013:923797.PubMedCentralPubMed

Nygaard U, Vestergaard C, Koppelhus U. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) of hands and feet in an 83-year-old man. Acta Derm Venereol. 2013;93:491–2.PubMedCrossRef

10.

Ozsahin M, Ataoglu S, Turan H. Unilateral RS3PE with young-onset rheumatoid arthritis. Semin Arthritis Rheum. 2011;40:e1.PubMedCrossRef

11.

Keenan RT, Hamalian GM, Pillinger MH. RS3PE presenting in a unilateral pattern: case report and review of the literature. Semin Arthritis Rheum. 2009;38:428–33.PubMedCrossRef

12.••

Kimura M, Tokuda Y, Oshiawa H, et al. Clinical characteristics of patients with remitting seronegative symmetrical synovitis with pitting edema compared to patients with pure polymyalgia rheumatica. J Rheumatol. 2012;39:148–53. This is a comparative study between RS3PE and PMR.PubMedCrossRef

13.

Bucaloiu ID, Olenginski TP, Harrington TM. Remitting seronegative symmetrical synovitis with pitting edema syndrome in a rural tertiary care practice: a retrospective analysis. Mayo Clin Proc. 2007;82:1510–5.PubMedCrossRef

14.

Okumura T, Tanno S, Ohhira M, Nozu T. The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan. Rheumatol Int. 2012;32:1695–9.PubMedCentralPubMedCrossRef

15.

Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2010;40:89–94.PubMedCrossRef

16.

Sugihara T, Ishizaki T, Hosoya T et al. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE). Rheumatology (Oxford) 2014 Oct 8. pii:keu395. [Epub ahead of print].

17.

Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis. 1999;58:230–6.PubMedCentralPubMedCrossRef

18.

Agarwal V, Dabra AK, Kaur R, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: ultrasonography as a diagnostic tool. Clin Rheumatol. 2005;24:476–9.PubMedCrossRef

19.

Gisserot O, Cremades S, Landais C, et al. RS3PE revealing recurrent non-Hodgkin’s lymphoma. Joint Bone Spine. 2004;71:424–6.PubMedCrossRef

20.

Tunc SE, Arslan C, Ayvacioglu NB, et al. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema (RS3PE syndrome): a report of two cases and review of the literature. Rheumatol Int. 2004;24:234–7.PubMedCrossRef

21.

Paira S, Graf C, Roverano S, Rossini J. Remitting seronegative symmetrical synovitis with pitting oedema: a study of 12 cases. Clin Rheumatol. 2002;21:146–9.PubMedCrossRef

22.

Vinci M, Malaguarnera L, Pistone G. RS3PE and ovarian cancer. Ann Rheum Dis. 2001;60:429–31.PubMedCentralPubMedCrossRef

23.

Goldenberg K, Rozenbaum M, Rosner I, et al. Remitting symmetric seronegative synovitis with pitting edema (RS3PE) secondary to non-Hodgkin’s lymphoma. Clin Exp Rheumatol. 1998;16:767–8.PubMed

24.

Cobeta-Garcia JC, Domingo-Morera JA, Martinez-Burgui J. RS3PE syndrome and chronic lymphoid leukaemia. Clin Exp Rheumatol. 1999;17:266–7.PubMed

25.

Chiappetta N, Gruber B. Remitting seronegative symmetrical synovitis with pitting edema associated with acute myeloid leukemia. J Rheumatol. 2005;32:1613–4.PubMed

26.

Ekenel M, Yavuz S, Karti S, et al. Remitting seronegative symmetrical synovitis with pitting oedema associated with chronic lymphocytic leukaemia. Clin Rheumatol. 2000;19:247–8.PubMedCrossRef

27.

Manganelli P, Delsante G, Bianchi G, et al. Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis. Clin Rheumatol. 2001;20:132–5.PubMedCrossRef

28.

Tabeya T, Sugaya T, Suzuki C et al. A case of angioimmunoblastic T-cell lymphoma with high serum VEGF preceded by RS3PE syndrome. Mod Rheumatol. 2013.

29.

Sibilia J, Friess S, Schaeverbeke T, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE): a form of paraneoplastic polyarthritis? J Rheumatol. 1999;26:115–20.PubMed

30.

Ethiopia A, Bell D. Gastric carcinoma in association with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol. 1999;26:1203–4.PubMed

31.

Tada Y, Sato H, Yoshizawa S, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with gastric carcinoma. J Rheumatol. 1997;24:974–5.PubMed

32.

Mattace-Raso FU, van der Cammen TJ. Remitting seronegative symmetrical synovitis with pitting oedema associated with lung malignancy. Age Ageing. 2007;36:470–1.PubMedCrossRef

33.

Olivo D, Mattace R. Concurrence of benign edematous polysynovitis in the elderly (RS3PE syndrome) and endometrial adenocarcinoma. Scand J Rheumatol. 1997;26:67–8.PubMedCrossRef

34.

Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45.PubMedCentralPubMedCrossRef

35.•

Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014;66:1472–81. This is a new study of malignancy rate in rheumatoid arthritis.PubMedCentralPubMedCrossRef

36.

Yamada T, Nakajima A, Inoue E, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31:1487–92.PubMedCrossRef

37.

Muller S, Hider SL, Belcher J, et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the general practice research database. Ann Rheum Dis. 2014;73:1769–73.PubMedCentralPubMedCrossRef

38.

Azar L, Khasnis A. Paraneoplastic rheumatologic syndromes. Curr Opin Rheumatol. 2013;25:44–9.PubMedCrossRef

39.•

Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10:662–70. This is a recent review of malignancies in rheumatology where the concept of paraneoplastic syndromes were defined, including RS3PE.PubMedCrossRef

40.

Hegazi MO, Saleh F, Al Rashidi A, Yaktien MM. Synovitis with pitting edema as the presenting manifestation of systemic lupus erythematosus. Lupus. 2014;23:1069–72.PubMedCrossRef

41.

Sugisaki K, Hirose T. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome following spontaneous rupture of a gouty tophus. Mod Rheumatol. 2008;18:630–3.PubMedCrossRef

42.

Fietta P, Manganelli P. Sjogren’s syndrome presenting as remitting seronegative symmetric synovitis with pitting edema (RS3PE): comment of the article by Choi et al. J Korean Med Sci. 2003;18:921.PubMedCentralPubMedCrossRef

43.

Billey T, Navaux F, Lassoued S. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) as the first manifestation of periarteritis nodosa. Report of a case. Rev Rhum Engl Ed. 1995;62:53–4.PubMed

44.

Koeger AC, Karmochkine M, Chaibi P. RS3PE syndrome associated with advanced ankylosing spondylitis. J Rheumatol. 1995;22:375–6.PubMed

45.

Matsuda M, Sakurai K, Fushimi T, et al. Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities. Clin Rheumatol. 2004;23:246–8.PubMedCrossRef

46.

Magy N, Michel F, Auge B, et al. Amyloid arthropathy revealed by RS3PE syndrome. Joint Bone Spine. 2000;67:475–7.PubMed

47.

Kato T, Ubara Y, Sawa N, et al. An abrupt onset of seropositive polyarthritis with prominent distal tenosynovitis concomitant with bronochiolitis obliterans organizing pneumonia (BOOP): consideration of the relationship with RS3PE syndrome. Intern Med. 2004;43:143–7.PubMedCrossRef

48.

Sakoda H, Ito S, Kanda H, et al. Association between type 1 diabetes mellitus and remitting seronegative symmetrical synovitis with pitting edema: a case report. Diabetes Res Clin Pract. 2011;91:e43–4.PubMedCrossRef

49.

Yamauchi K, Sato Y, Yamashita K, et al. RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases. Diabetes Care. 2012;35:e7.PubMedCentralPubMedCrossRef

50.

Smyth D, Rehman R, Remund K, Egan J. Remitting seronegative symmetrical synovitis with pitting oedema associated with rifampicin. Ir J Med Sci. 2011;180:585–6.PubMedCrossRef

51.

Mainali NR, Schmidt TR, Alweis R, George DL. Novel development of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome due to insulin therapy. Am J Case Rep. 2014;15:119–22.PubMedCentralPubMedCrossRef

52.

El Mahou S, Popa L, Constantin A, et al. Remitting seronegative symmetrical synovitis pitting oedema after BCG instillation. Clin Rheumatol. 2006;25:566–7.PubMedCrossRef

53.

Perandones CE, Colmegna I, Arana RM. Parvovirus B19: another agent associated with remitting seronegative symmetrical synovitis with pitting edema. J Rheumatol. 2005;32:389–90.PubMed

54.

Torres A, Cuende E, De Pablos M, et al. Remitting seronegative symmetrical synovitis with pitting edema associated with subcutaneous Streptobacillus moniliformis abscess. J Rheumatol. 2001;28:1696–8.PubMed

55.

Mittal K, Ebos J, Rini B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin Oncol. 2014;41:235–51.PubMedCrossRef

56.

Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265:H586–92.PubMed

57.

Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64:1653–5.PubMedCentralPubMedCrossRef

58.

Horai Y, Honda M, Nishino A, et al. Anti-citrullinated protein antibody-positive rheumatoid arthritis associated with RS3PE syndrome-like symptoms and an elevated serum vascular endothelial growth factor level in a patient with myasthenia gravis. Intern Med. 2014;53:895–8.PubMedCrossRef

59.

Oide T, Ohara S, Oguchi K, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol. 2004;22:91–8.PubMed

60.

Origuchi T, Arima K, Kawashiri SY, et al. High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol. 2012;22:584–8.PubMedCrossRef

61.

Baumgartner I, Rauh G, Pieczek A, et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med. 2000;132:880–4.PubMedCrossRef

62.

van Schaardenburg D, Breedveld FC. Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum. 1994;23:367–78.PubMedCrossRef

63.

Finnell JA, Cuesta IA. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a review of the literature and a report of three cases. J Foot Ankle Surg. 2000;39:189–93.PubMedCrossRef

64.

Queiro R. RS3PE syndrome: a clinical and immunogenetical study. Rheumatol Int. 2004;24:103–5.PubMedCrossRef

65.

Guma M, Casado E, Tena X, Olive A. RS3PE: six years later. Ann Rheum Dis. 1999;58:722–3.PubMedCentralPubMedCrossRef

Titel: RS3PE: Clinical and Research Development
verfasst von: Hongbin Li
Roy D. Altman
Qingping Yao
Publikationsdatum: 01.08.2015
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 8/2015
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-015-0525-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

RS3PE: Clinical and Research Development

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2015

Imaging in Giant Cell Arteritis

Implementation of Functional Genomics for Bench-to-Bedside Transition in Osteoarthritis

Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis

Medical Plant Extracts for Treating Knee Osteoarthritis: a Snapshot of Recent Clinical Trials and Their Biological Background

HCV Treatments and Their Integration Into Rheumatology

Novel Insights into Osteoarthritis Joint Pathology from Studies in Mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin